Historique de carrière de Trine Bartholdy
Anciens postes connus de Trine Bartholdy
Sociétés | Poste | Début | Fin |
---|---|---|---|
Sunstone Capital A/S
Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Director of Investments | 01/04/2007 | 01/04/2011 |
Private Equity Investor | 31/07/2009 | 01/04/2011 | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Directeur/Membre du Conseil | - | - |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Directeur/Membre du Conseil | 14/04/2011 | - |
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 14/10/2009 | - |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | Directeur/Membre du Conseil | - | - |
Danmarks Eksport- og Investeringsfond
Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Private Equity Investor | - | - |
Formation de Trine Bartholdy
Copenhagen Business School | Graduate Degree |
Statistiques
Internationale
Danemark | 5 |
Royaume-Uni | 2 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 4 |
Private Equity Investor | 2 |
Director of Investments | 1 |
Sectorielle
Health Technology | 5 |
Finance | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 6 |
---|---|
Danmarks Eksport- og Investeringsfond
Danmarks Eksport- og Investeringsfond Investment ManagersFinance Danmarks Eksport- og Investeringsfond (EIFO) is a venture capital subsidiary of Government of Denmark and founded in 1992. The firm is headquartered in Hellerup, Denmark. | Finance |
Sunstone Capital A/S
Sunstone Capital A/S Investment ManagersFinance Sunstone Capital A/S (Sunstone) is an independent venture capital firm headquartered in Copenhagen, Denmark. The firm was founded in 2007 by Peter Benson, Sten Verland, and Søren Lemonius, and invests on behalf of a group of institutional investors. | Finance |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | Health Technology |
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Health Technology |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |
- Bourse
- Insiders
- Trine Bartholdy
- Expérience